Paula Cramer
Impact in
- Genetics top 0.1%
- Chronic Lymphocytic Leukemia Research
-
- Lymphoma Diagnosis and Treatment
Papers in
- Genetics 97
- Chronic Lymphocytic Leukemia Research 97
-
- Lymphoma Diagnosis and Treatment 2
- Co-authors
- Michael J. Hallek (55 shared papers)Barbara F. Eichhorst (47 shared papers)Stephan Stilgenbauer (34 shared papers)Kirsten Fischer (36 shared papers)Clemens‐Martin Wendtner (26 shared papers)Jasmin Bahlo (24 shared papers)Hartmut Doehner (11 shared papers)Anna‐Maria Fink (25 shared papers)
- Journals
- Blood (25 papers)Leukemia (8 papers)Journal of Clinical Oncology (7 papers)Haematologica (6 papers)Hematological Oncology (5 papers)
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
Paula Cramer
97 papers receiving 5.7k citations
Paula Cramer's Hit Papers
Peers
Comparison fields: 5 of 90
- Genetics 4.4k
- Pathology and Forensic Medicine 398
- Hematology 143
- Oncology 208
- Immunology 139
Countries citing papers authored by Paula Cramer
This map shows the geographic impact of Paula Cramer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paula Cramer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paula Cramer more than expected).
Fields of papers citing papers by Paula Cramer
This network shows the impact of papers produced by Paula Cramer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paula Cramer. The network helps show where Paula Cramer may publish in the future.
Co-authors
The 25 scholars most cited alongside Paula Cramer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 99 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia Hit paper breakdown → | 2014 | 1438 |
| 2 | Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial Hit paper breakdown → | 2015 | 713 |
| 3 | 2015 | 363 | |
| 4 | 2012 | 359 | |
| 5 | 2011 | 322 | |
| 6 | 2017 | 214 | |
| 7 | 2019 | 200 | |
| 8 | 2018 | 169 | |
| 9 | 2016 | 149 | |
| 10 | 2010 | 132 | |
| 11 | 2018 | 101 | |
| 12 | 2014 | 100 | |
| 13 | 2014 | 95 | |
| 14 | 2018 | 95 | |
| 15 | 2016 | 94 | |
| 16 | 2020 | 87 | |
| 17 | 2018 | 81 | |
| 18 | 2021 | 76 | |
| 19 | 2018 | 72 | |
| 20 | 2009 | 61 |
About Paula Cramer
Paula Cramer is a scholar working on Genetics, Pathology and Forensic Medicine, Emergency Medicine, Nuclear Energy and Engineering and Waste Management and Disposal, having authored 99 papers that have together received 5.8k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (97 papers), Lymphoma Diagnosis and Treatment (2 papers) and Hematological disorders and diagnostics (1 paper). The work is most often cited by research in Genetics (4.4k citations), Pathology and Forensic Medicine (398 citations), Hematology (143 citations), Oncology (208 citations) and Immunology (139 citations). Paula Cramer has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Michael J. Hallek, Barbara F. Eichhorst, Stephan Stilgenbauer, Kirsten Fischer, Clemens‐Martin Wendtner, Jasmin Bahlo, Hartmut Doehner, Anna‐Maria Fink, Petra Langerbeins and Raymonde M. Busch. Their work appears in journals such as Blood, Leukemia, Journal of Clinical Oncology, Haematologica and Hematological Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.